Renal Cell Carcinoma with Skull Base Metastasis Preceded by Paraneoplastic Signs in a Chronic Hemodialysis Patient

Internal Medicine

Volumn 40, Issue 9, 2001, Pages 924-930

  Endo, Kazunori ^a   Okano, Ryo ^a   Kuroda, Yutaka ^a   Yamada, Shigeki ^a   Tabei, Kaoru ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Acquired cystic kidney; Alkaline phosphatase; C reactive protein; Hypoglossal nerve palsy; Interleukin 6

Indexed keywords

ARTICLE; BLOOD; CASE REPORT; CHRONIC DISEASE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; KIDNEY CARCINOMA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; PARANEOPLASTIC SYNDROME; PATHOLOGY; RADIOGRAPHY; RENAL REPLACEMENT THERAPY; SKULL BASE TUMOR;

CARCINOMA, RENAL CELL; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES, CYSTIC; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; RENAL DIALYSIS; SKULL BASE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0035461152     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.924     Document Type: Article

References (27)

1. Dunnill MS, Millard PR, Oliver D. Acquired cystic disease of the kidneys: A hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol 30: 868–877, 1977.
2. Ishikawa I. Acquired cystic disease and renal tumors in long-term dialysis patients, in: Complications of Long-term Dialysis. Brown EA, Parfrey PS, Eds. Oxford University Press, Oxford, 1999: 145–169.
3. Ishikawa I. Uremic acquired renal cystic disease, natural history and complications. Nephron 58: 257–267, 1991.
4. Garnick MB, Richie JP. Renal Neoplasia, in: The Kidney. 5th ed. Brenner BM, Ed. WB Saunders, Philadelphia, 1996: 1959–1977.
5. Blay JY, Rossi JF, Wijdenes J., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72: 424–430, 1997.
6. Greenberg HS, Deck MDF, Vikram B., Chu FCH, Posner JB. Metastasis to the base of the skull: Clinical findings in 43 patients. Neurology 31: 530–537, 1981.
7. 99mTc-SPECT in the diagnosis of skull base metastasis. Neurology 48: 1326–1330, 1997.
8. Swanson DA, Orovan WL, Johnson DE, Giacco G. Osseous metastases secondary to renal cell carcinoma. Urology 18: 556–561, 1981.
9. Fukumoto M., Osaki Y., Yoshida D., et al. Dual-isotope SPECT diagnosis of a skull-base metastasis causing isolated unilateral hypoglossal nerve palsy. Ann Nucl Med 12: 213–216, 1998.
10. Shiraishi T., Yanagida H., Takada K., Yasuhara Y. Unusual cranial metastasis from hepatoma presenting as isolated unilateral hypoglossal nerve paresis. Neurol Med Chir (Tokyo) 32: 166–168, 1992.
11. Brillman J., Valeriano J., Adatepe MH. The diagnosis of skull base metastases by radionuclide bone scan. Cancer 59: 1887–1891, 1987.
12. Ransom DT, Dinapoli RP, Richardson RL. Cranial nerve lesions due to base of the skull metastases in prostate carcinoma. Cancer 65: 586–589, 1990.
13. Moris G., Roig C., Misiego M., Alvarez A., Berciano J., Pascual J. The distinctive headache of the occipital condyle syndrome: A report of four cases. Headache 38: 308–311, 1998.
14. Mubaidin SI, Sunna JB, Beiruti MA, Shennak MM, Ayoub MS. Renal cell carcinoma presenting as Garcin’s syndrome. J Neurol Neurosurg Psychiatry 53: 613–614, 1990.
15. Vikram B., Chu FCH. Radiation therapy for metastases to the base of the skull. Radiology 130: 465–468, 1979.
16. Stauffer MH. Nephrogenic hepatosplenomegaly. Gastroenterology 40: 694, 1961 (Abstract).
17. Walsh PN, Kissane JM. Nonmetastatic hypernephroma with reversible hepatic dysfunction. Arch Intern Med 122: 214–222, 1968.
18. Weber J., Gunn H., Yang J., et al. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 15: 292–302, 1994.
19. Takenawa J., Kaneko Y., Fukumoto M., et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 83: 1668–1672, 1991.
20. Blay JY, Negrier S., Combaret V., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317–3322, 1992.
21. Walther MM, Johnson B., Culley D., et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol 159: 718–722, 1998.
22. Docci D., Bilancioni R., Buscaroli A, et al. Elevated serum levels of C-reactive protein in hemodialysis patients. Nephron 56: 364–367, 1990.
23. McLntyre C, Harper I, Macdougall IC, Raine AEG, Williams A, Baker LRI. Serum C-reactive protein as a marker for infection and inflammation in regular dialysis patients. Clin Nephrol 48: 371–374, 1997.
24. Naik RB, Gosling P, Price CP. Comparative study of alkaline phosphatase isoenzymes, bone histology, and skeletal radiography in dialysis bone disease. Br Med J 1: 1307–1310, 1977.
25. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 39: 954–960, 1991.
26. Cavaillon JM, Poignet JL, Fitting C, Delons S. Serum interleukin-6 in long-term hemodialyzed patients. Nephron 60: 307–313, 1992.
27. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 31: 93–100, 1998.